Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro

Mika Okamoto 1, Masaaki Toyama 1, Masanori Baba 2

Division of Antiviral Chemotherapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, 890-8544, Japan

ARTICLE INFO
Keywords:
COVID-19
SARS-CoV-2
Cenicriviroc
Chemokine receptor antagonist
Cytokine storm

ABSTRACT
Cenicriviroc (CVC) is a small-molecule chemokine receptor antagonist with highly potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity through antagonizing C-C chemokine receptor type 5 (CCR5) as a coreceptor of HIV-1. CVC also strongly antagonizes C-C chemokine receptor type 2b (CCR2b), thereby it has potent anti-inflammatory and immunomodulatory effects. CVC is currently under clinical trials in the patients for treatment of nonalcoholic steatohepatitis, in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis. In this study, CVC was examined for its inhibitory effect on the replication of SARS-CoV-2, the causative agent of COVID-19, in cell cultures and found to be a selective inhibitor of the virus. The 50% effective concentrations of CVC were 19.0 and 2.9 μM in the assays based on the inhibition of virus-induced cell destruction and viral RNA levels in culture supernatants of the infected cells, respectively. Interestingly, the CCR5-specific antagonist maraviroc did not show any anti-SARS-CoV-2 activity. Although the mechanism of SARS-CoV-2 inhibition by CVC remains to be elucidated, CCR2b does not seem to be its target molecule. Considering the fact that the regulation of excessive immune activation is required to treat COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.

1. Introduction
The pandemic of severe pneumonia (COVID-19) caused by the transmission of the new coronavirus SARS-CoV-2 is a serious threat to humanity (Di Gennaro et al., 2020; Harapan et al., 2020; Helmy et al., 2020). At present, no vaccines exist, and the nucleoside analog remdesivir (RDV) has recently been approved for treatment of SARS-CoV-2 infection (Grein et al., 2020). RDV has broad-spectrum antiviral activity against several viruses, including Ebola virus and coronaviruses. In addition to RDV, there is an attempt to treat COVID-19 with existing drugs developed for other purposes. These include hydroxychloroquine and chloroquine (Pastick et al., 2020), the anti-influenza virus agent favipiravir (FPV) (Pilkington et al., 2020), and the human immunodeficiency virus type 1 (HIV-1) protease inhibitor lopinavir/ritonavir (Cao et al., 2020). More recently, the anti-parasitic agent ivermectin has been shown to inhibit SARS-CoV-2 replication in cell cultures (Caly et al., 2020). However, these drugs are not optimized for SARS-CoV-2, so that they may have inevitable adverse effects due to the requirement of higher dosages. Furthermore, these antiviral agents must be used at an early stage of infection, since severe deterioration of pneumonia in some patients is considered to be closely associated with not viral replication but “cytokine storm” caused by dysregulated and excessive cytokine release from activated immune cells (Ye et al., 2020). Therefore, the use of anti-inflammatory and immunomodulatory agents is mandatory in the late stage of this disease (Alijotas-Reig et al., 2020).

We have examined several compounds for their inhibitory effect on SARS-CoV-2 replication in cell cultures and found that the chemokine receptor antagonist cenicriviroc (CVC) inhibits the replication of SARS-CoV-2. CVC is a C-C chemokine receptor type 5 (CCR5) antagonist with potent and selective anti-HIV-1 activity (Baba et al., 2005). In addition, CVC antagonizes not only CCR5 but also C-C chemokine receptor type 2b (CCR2b). Since CCR2b is the receptor of monocyte chemoattractant protein 1 (MCP-1), CVC exerts anti-inflammatory and immunomodulatory effects in vivo (Dawson et al., 2003; Xia and Sui, 2009). In fact, CVC is currently under clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), in which immune cell activation and dysregulation of proinflammatory cytokines play an important role in its pathogenesis (Pedrosa et al., 2020).
2. Materials and Methods

2.1. Cells and virus

VeroE6 cell line expressing transmembrane protease serine 2 (VeroE6/TMPRSS2) highly susceptible to SARS-CoV-2 infection (Matsumiya et al., 2020) was obtained from Japanese Collection of Research Bioresources (JCRB) Cell Bank in Japan (JCRB no. JCRB1819) and used for virus propagation and antiviral assays after removal of mycoplasma contamination. Vero cells were also used for experiments. The cells were cultured in Dulbecco’s modified Eagle medium (Nacalai Tesque, Kyoto, Japan) supplemented with 5% heat-inactivated fetal bovine serum, 100 U/ml penicillin G, 100 μg/ml streptomycin, and 1 mg/ml G418 (Nacalai Tesque). For antiviral assays, the cells were cultured in the absence of G418. SARS-CoV-2 (WK-521 strain, GISAID database ID EPI_ISL_408667), a clinical isolate from a COVID-19 patient, was provided by National Institute of Infectious Diseases, Tokyo, Japan (Matsumiya et al., 2020). The infectious virus titer was determined in VeroE6/TMPRSS2 cells and expressed as 50% cell culture infectious dose (CCID₅₀) per ml.

2.2. Reagents

CVC and maraviroc (MRV) were purchased from MedChemExpress (Monmouth Junction, NJ). The nucleotide/nucleoside analogs RDV and FPV were obtained from ChemScence (Monmouth Junction, NJ) and Selleck Chemicals (Houston, TX), respectively. MCP-1 was purchased from PetpoTech (Rocky Hill, NJ). MRV is the CCR5 antagonist clinically approved for treatment of HIV-1 infection (Woollard and Kanmogne, 2015). Except for MCP-1, these compounds were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 20 mM or higher to exclude the cytotoxicity of DMSO and stored at 20 °C until use. MCP-1 was dissolved in distilled water.

2.3. Antiviral assays

VeroE6/TMPRSS2 cells (2 × 10⁴ cells/well) were cultured in a 96-well microtiter plate and incubated at 37 °C. After 24 h, the cells were mock-infected or infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.01 and cultured in the absence or presence of various concentrations of test compounds. After 3 days, the number of viable cells was determined by a tetrazolium dye method. Briefly, 100 μl of cell culture medium was removed from each well, and 10 μl of water-soluble tetrazolium dye solution (Dojindo, Kumamoto, Japan) was added. After incubation at 37 °C for 2 h, the absorbance was read at two wavelengths (450 and 620 nm) with a microplate reader (Pauwels et al., 1988). The 50% effective concentration (EC₅₀) of each compound was calculated from a dose-dependent curve based on the viability of infected and uninfected cells. All experiments using SARS-CoV-2 were conducted in biosafety level 3 (BSL3) facilities of Kagoshima University.

For immunofluorescence microscopy, Vero cells (2 × 10⁴ cells/well) were cultured in a microtiter plate and incubated. After 24 h, the cells were mock-infected or infected with SARS-CoV-2 at a MOI of 0.1 in the absence of CVC and incubated. After 2 h, the cells were washed with phosphate buffered saline (PBS) to remove unadsorbed virus particles and further incubated in the absence or presence of 20 μM CVC. After 3 days, the cells were
overnight at 4 °C with an anti-SARS-CoV-2 nucleocapsid rabbit antibody (GeneTex, Irvine, CA). After incubation, the cells were washed with PBS and stained with the secondary antibody goat anti-rabbit IgG H&L (Alexa Fluoro® 488; Abcam, Cambridge, UK). The cells were washed with PBS, stained with 4′,6-diamidino-2-phenylindole (DAPI; Bio-Rad, Hercules, CA), and observed under a fluorescent microscope (BZ-X800; Keyence, Osaka, Japan).

2.4. Determination of viral RNA levels

The inhibitory effect of compounds on SARS-CoV-2 replication was also evaluated by the viral RNA levels in culture supernatants of the infected cells. VeroE6/TMPRSS2 cells were infected with the virus and incubated for 3 days in the absence or presence of test compounds, as described above. Ten μl of each culture supernatant was mixed with 10 μl of SideStep Lysis and Stabilization Buffer (Agilent Technologies, Santa Clara, CA) and diluted with 80 μl of distilled water. The amount of viral RNA was measured by real-time reverse transcription polymerase chain reaction (RT-PCR) using TaqMan Gene Expression Cells-to-CT™ Kit (Thermo Fisher Scientific, Waltham, MA), according to the manufacturer’s protocol except for its cell lysis step. The primer pair 5′-AAATTTGGGACACAGAACC-3′ and 5′-TGGCAAGCTGTAGGTCAAC-3′ and the probe 5′-FAM-ATGTCGCGCATTGGCATGGA-TAMRA-3′ were used for real-time PCR (Shirato et al., 2020). The SARS-CoV-2 plasmid control for creating the calibration curve was obtained from Integrated DNA Technologies (Coralville, IA). To examine the virus growth kinetics, culture supernatants were collected on days 1, 2, and 3 after virus infection. Viral RNA was extracted and purified using RNAzol® (Molecular Research Center, Cincinnati, OH) and Direct-zol RNA MicroPrep Kit (Zymo Research, Irvine, CA), according to the manufacturer’s protocol. The purified RNA was subjected to real-time RT-PCR to determine the amount of viral RNA, as described above.

3. Results

When VeroE6/TMPRSS2 cells were infected with SARS-CoV-2 and incubated in the absence of compounds for 3 days, the cells were completely destroyed by the virus-induced cytopathic effect (Fig. 1B). Such cell destruction was not observed for the infected cells in the presence of 20 μM CVC, although some morphological changes were identified (Fig. 1D). In contrast, MRV did not inhibit the virus-induced cell destruction even at 40 μM (Fig. 1F). The EC₅₀ of CVC and MRV were 19 ± 0.2 and >40 μM, respectively, based on the inhibition of virus-induced cell destruction (Table 1). Both compounds did not show apparent cytotoxicity at concentrations up to 80 μM. Dose-dependent protection of the infected cells from virus-induced cell destruction was observed for CVC but not for MRV (Fig. 2). These results indicate that CVC is a selective inhibitor of SARS-CoV-2 replication. As previously reported (Wang et al., 2020), RDV proved to be a potent and selective inhibitor of SARS-CoV-2 replication in our assay, whereas FPV did not show any selective inhibition even at a concentration of 80 μM (Table 1 and Fig. S1).

The anti-SARS-CoV-2 activity was also examined by the inhibition of viral antigen expression in Vero cells. Vero cells is less susceptible to SARS-CoV-2 replication than VeroE6/TMPRSS2 cells. In fact, Vero cells were not destroyed by the virus-induced cytopathic effect on day 3 after infection (Fig. 3A). However, viral antigen expression was observed for many cells in the absence of CVC (Fig. 3B). In contrast, the antigen expression was completely inhibited in the presence of 40 μM CVC (Fig. 3D). When the anti-SARS-CoV-2 activity of CVC was evaluated by the viral RNA levels in culture supernatants of the infected cells, CVC significantly and dose-dependently reduced the amount of viral RNA in culture supernatants (Fig. 4A). Its EC₅₀ in this assay was 2.9 μM, and
more than 95% inhibition was achieved by CVC at a concentration of 10 μM. In contrast, MRV did not reduce the viral RNA levels at concentrations up to 40 μM (Fig. 4B). To confirm the inhibitory effect of CVC on SARS-CoV-2 replication, the viral growth kinetics was investigated, in which the culture supernatants were collected every day and examined for their viral RNA levels. As shown in Fig. 5, CVC but not MRV suppressed the replication of SARS-CoV-2 in infected VeroE6/TMPRSS2 cells in a dose dependent manner. On the other hand, it appeared that MRV slightly accelerated the growth of SARS-CoV-2 at a concentration of 20 μM.

4. Discussion

In 2005, we have reported that the small molecule and orally bioavailable CCR5 antagonist CVC inhibits HIV-1 replication at subnanomolar concentrations in vitro (Baba et al., 2005). The anti-HIV-1 activity of CVC is attributed to the inhibition of viral entry using CCR5 as a coreceptor. However, different from other anti-HIV-1 CCR5 antagonists such as MRV, CVC also suppresses the binding of MCP-1 to CCR2b-expressing cells. This unique feature of CVC encouraged its manufacturer to develop this compound as an agent for treatment of NASH. A recent randomized, placebo-controlled trial of CVC for treatment of NASH demonstrated that twice as many subjects achieved improvement in fibrosis and no worsening of steatohepatitis compared with placebo (Friedman et al., 2018; Tacke, 2018). Safety and tolerability of CVC were found to be comparable to placebo, suggesting that it can be administered safely to COVID-19 patients for preventing severe deterioration of pneumonia due to the cytokine storm. In fact, alveolar macrophage-borne MCP-1 was reported to be a key agent in the initiation of the systemic inflammation of alveolar hypoxia in rats, and a CCR2b receptor antagonist prevented the mesenteric inflammation of alveolar hypoxia (Chao et al., 2011).

Furthermore, a recent study on transcriptome sequencing of the RNAs isolated from the bronchoalveolar lavage fluid and peripheral blood mononuclear cells specimens of COVID-19 patients revealed the association between its pathogenesis and excessive cytokine release including MCP-1 (Xiong et al., 2020). It will be claimed that the anti-SARS-CoV-2 activity of CVC in vitro is insufficient for the treatment of COVID-19 patients. However, our antiviral assay system using VeroE6/TMPRSS2 cells based on the inhibition of virus-induced cell destruction appears to be aggressive. SARS-CoV-2 uses the SARS-CoV receptor angiotensin-converting enzyme 2 for entry and the serine protease TMPRSS2 for S protein priming. This explains why VeroE6/TMPRSS2 are highly susceptible to SARS-CoV-2 infection (Matsuyama et al., 2020). When the parental cell line Vero was infected with SARS-CoV-2 at a MOI of 0.1 and cultured for 4 days, approximately half of the infected cells survived even in the absence of compounds (Fig. S2). Under such experimental conditions, CVC completely inhibited virus-induced cell destruction at 10 μM in Vero cells. The EC50 values of anti-SARS-CoV-2 compounds reported to date are rather high in VeroE6/TMPRSS2 cells. For instance, the EC50s of RDV and hydroxychloroquine were 1.1 and 22.5 μM, respectively (Table 1 and data not shown). The broad-spectrum anti-RNA virus agent FPV was not inhibitory to SARS-CoV-2 replication even at 80 μM (Table 1 and Fig. S1), which is consistent with a previous report (Choy et al., 2020). The anti-SARS-CoV-2 activity of CVC was more obvious, when determined by the inhibition of viral RNA levels in culture supernatants. Its EC50 was 2.9 μM (Fig. 4), which was similar to those of RDV (1.9 μM) and ivermectin (2.2–2.8 μM) (data not shown and Caly et al., 2020, respectively). Thus, although the anti-SARS-CoV-2 activity of CVC in vitro is modest, we cannot exclude the possibility that CVC
exhibits some antiviral efficacy in COVID-19 patients.

The target molecule of CVC remains to be elucidated. Our preliminary studies on its mechanism of action revealed that CVC did not interfere with the entry of SARS-CoV-2 (data not shown). Unlike HIV-1, CCR5 is not the target of CVC for inhibition of SARS-CoV-2 replication, since another potent CCR5 antagonist MRV was totally inactive (Figs. 2B and 4B). Furthermore, MCP-1 could not block SARS-CoV-2 infection (Fig. 2C), suggesting that CCR2b is not the target molecule either. Further studies, such as a time-of-addition experiment and biochemical approaches, are required to elucidate the mechanism of action, and they are currently in progress.

In conclusion, in addition to the potent anti-inflammatory activity of CVC in vivo, the present study has identified its anti-SARS-CoV-2 activity in vitro. Since not only the inhibition of viral replication but also the control of excessive immune activation is mandatory to save COVID-19 patients at the late stage of the disease, CVC should be further pursued for its potential in the treatment of SARS-CoV-2 infection.

Acknowledgments

We thank National Institutes of Biomedical Innovation, Health and Nutrition and National Institute of Infectious Diseases for kindly providing VeroE6/TMPRSS2 cells and SARS-CoV-2 (WK-521 strain), respectively. Kagoshima University is applying for a patent of CVC as a SARS-CoV-2 inhibitor, and M.O., M.T. and M.B. are its inventors.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.antiviral.2020.104902.

References

Alijotas-Reiga, J., Esteve-Valverde, E., Beliznaf, C., Selva-O’Callaghan, A., Pardos-Gea, J., Qunzana, A., Mekinaia, A., Annunciation-Llunell, A., Miro-Murg, F., 2020. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun. Rev. 102569.

Baba, M., Takashima, K., Miyake, H., Kanzaki, N., Teshima, K., Wang, X., Shiraishi, M., Iizawa, Y., 2005. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob. Agents Chemother. 49 (11), 4584–4591.

Calý, L., Druce, J.D., Catton, M.G., Jans, D.A., Wagstaff, K.M., 2020. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 178, 104787.

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F.G., Horby, P.W., Zhang, D., Wang, C., 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N. Engl. J. Med. 382 (19), 1787–1799.

Chao, J., Donham, F., van Rooijen, N., Wood, J.G., Gonzalez, N.C., 2011. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the
systemic inflammation of acute alveolar hypoxia. Am. J. Respir. Cell Mol. Biol. 45 (1), 53–61.

Choy, K.T., Wong, A.Y., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K.P.Y., Chu, D.K.W., Chan, M.C.W., Cheung, P.P., Huang, X., Peiris, M., Yen, H.L., 2020. Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro. Iver178, 104786.

Dawson, J., Militz, W., Mir, A.K., Wiessner, C., 2003. Targeting monocyte chemoattractant protein-1 signaling in disease. Expert Opin. Ther. Targets 7 (1), 35–48.

Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., Smith, L., 2020. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. Int. J. Environ. Res. Publ. Health 17 (8), E2690.

Friedman, S.L., Rutziu, V., Harrison, S.A., Abdelmalek, M.F., Aithal, G.P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K.V., Czaja, A., Simon, K., Fischer, L., Melchor-Khan, L., Vest, J., Wiens, B.L., Vig, F., Seyedkazemi, S., Goodman, Z., Wong, V.W., Loomba, R., Tacke, F., Sanaly, A., Lefebvre, E., 2018. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67 (5), 1754–1767.

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M.L., Lescure, F.X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemund, A., Redinski, J., Ahmed, S., Bennett, J., Chelliah, D., Chen, D., Chihara, S., Cohen, S.H., Cunningham, J., D’Arminio Monforte, A., Izzaim, S., Kato, H., Lapudula, G., L’Her, E., Maeno, T., Majumder, S., Massari, M., Mora-Rillo, M., Mutoh, Y., Nguyen, D., Verweij, E., Zoufaly, A., Osinusi, A.O., DeZure, A., Zhao, Y., Zhong, L., Chokkalingam, A., Elboudwarej, E., Telep, L., Timbs, L., Hense, I., Sellers, S., Cao, H., Tan, S.K., Winterbourne, L., Desai, P., Mera, R., Gagger, A., Myers, R.P., Brainard, D.M., Childs, R., Flanigan, T., 2015. Maraviroc: a review of its use in HIV infection – potential treatment in the COVID-19 pandemic? J. Virus Erad. 6 (2), 45–51.

Kuroda, M., Suzuki, T., Kageyama, T., Takeda, M., 2020. Enhanced isolation of the Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Pastick, K.A., Okafor, E.C., Wang, F., Lofgren, S.M., Skipper, C.P., Nicol, M.R., Pullen, M. F., Rajsinghain, R., McDonald, E.G., Lee, T.C., Schwartz, I.S., Kelly, I.E., Lother, S. A., Mitija, O., Letang, E., Abassi, M., Boulware, D.R., 2020. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect. Dis. 7 (4) ofaa130.

Loomba, R., Ratziu, V., Kochuparambil, J., Fischer, L., Vaidyanathan, S., Anstee, Q. M., 2020. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial. Contemp. Clin. Trials 88, 105889.

Mir, A.K., Wiessner, C., 2020. Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn. J. Infect. Dis. 100 (1), 1–3.

Nakatsu, Y., Mori, Y., Kageyama, T., Matsuura, S., Nakatsu, M., Nakatsu, Y., Mori, Y., Kageyama, T., Matsuura, S., Takeda, M., 2020. Development of genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan. Jpn. J. Infect. Dis. 100 (1), 1–3.

Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdevijn, P., Desmyter, J., De Clercq, E., 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20 (4), 309–321.

Pastick, K.A., Okafor, E.C., Wang, F., Lofgren, S.M., Skipper, C.P., Nicol, M.R., Pullen, M. F., Rajsinghain, R., McDonald, E.G., Lee, T.C., Schwartz, I.S., Kelly, I.E., Lother, S. A., Mitija, O., Letang, E., Abassi, M., Boulware, D.R., 2020. Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open Forum Infect. Dis. 7 (4) ofaa130.